EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Bispecific Antibody and Antibody-Drug Conjugate as Novel Candidates for Treating Pancreatic Ductal Adenocarcinoma

Hyeryeon Seo, Dabin Go, Se Young Jung, Shinwoo Han, Van Quy Nguyen, Minseok Kwak iD, Wooram Um iD

Biomolecules · 20.10.2025 · 15 (10) · 1477

DOI: 10.3390/biom15101477 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 20.10.2025. Verfasst von Hyeryeon Seo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, Pukyong National University, Busan 48513, Republic of Korea. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Carcinoma, Pancreatic Ductal, Immunoconjugates, Pancreatic Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 167 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Pukyong National University, Pukyong National University Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, characterized by a dense and immunosuppressive tumor microenvironment. With the limited actions of drugs and conventional monovalent antibodies, the success of existing cancer therapies is restricted so far. Recently, bispecific antibodies (BsAbs) have emerged as a promising therapeutic platform, capable of overcoming the limitations of current PDAC treatments by engaging T cells and delivering drugs to multiple targets in a selective manner. Furthermore, the recruitment of additional payloads expands their therapeutic potential, offering more selective drug delivery and presenting new possibilities for treating PDAC. However, a limited number of relevant studies and a lack of comprehensive research have hindered trials for the development of BsAbs and bispecific antibody-drug conjugates (BsADCs) in PDAC therapeutics. This review aims to provide the characteristics of BsAbs and BsADCs and their recent applications in PDAC treatment. Additionally, frequent targets of PDAC treatments will be discussed to suggest how to design BsAbs and BsADCs for PDAC treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificCarcinoma, Pancreatic DuctalImmunoconjugatesPancreatic NeoplasmsHumansAnimalsTumor Microenvironment

Stichwörter der Autor:innen

antibody-drug conjugatebispecific antibodypancreatic ductal adenocarcinoma

Substanzen

Antibodies, BispecificImmunoconjugates

Autor:innen und Institutionen

  • Department of Biotechnology, Pukyong National University, Busan 48513, Republic of Korea.
  • Faculty of Chemical and Food Technology, University of Technology and Education, Ho Chi Minh City 75603, Vietnam.
  • Department of Chemistry and Industry 4.0 Convergence Bionics Engineering, Pukyong National University, Busan 48513, Republic of Korea.

ORCID-Profile: Minseok Kwak, Wooram Um

Förderung

  • National Research Foundation of Korea
  • Pukyong National University
  • Pukyong National University Research Fund

Zitieren

APA

Seo, H., Go, D., Jung, S. Y., Han, S., Nguyen, V. Q., Kwak, M., & Um, W. (2025). Bispecific Antibody and Antibody-Drug Conjugate as Novel Candidates for Treating Pancreatic Ductal Adenocarcinoma. Biomolecules, 15(10), 1477. https://doi.org/10.3390/biom15101477

Vancouver

Seo H, Go D, Jung SY, Han S, Nguyen VQ, Kwak M, et al. Bispecific Antibody and Antibody-Drug Conjugate as Novel Candidates for Treating Pancreatic Ductal Adenocarcinoma. Biomolecules. 2025;15(10):1477. doi:10.3390/biom15101477

BibTeX
@article{Seo2025,
  author = {Seo, Hyeryeon and Go, Dabin and Jung, Se Young and Han, Shinwoo and Nguyen, Van Quy and Kwak, Minseok and Um, Wooram},
  title = {Bispecific Antibody and Antibody-Drug Conjugate as Novel Candidates for Treating Pancreatic Ductal Adenocarcinoma},
  journal = {Biomolecules},
  year = {2025},
  volume = {15},
  number = {10},
  pages = {1477},
  doi = {10.3390/biom15101477}
}
Kostenlos starten →